Top Markets
#1 ADO Protocol ADO Protocol +329.37%
#2 GoPlus Security GoPlus Security +53.93%
#3 Verus Coin Verus Coin +43.47%
#4 Nockchain Nockchain +40.54%
#5 The Black Bull The Black Bull +39.50%
#6 Starpower Starpower +35.61%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +34.02%
#8 Tutorial Tutorial +27.75%
#9 Fake World Assets Fake World Assets +24.98%
#10 GAIB AID GAIB AID +24.67%
Coin of the day
ADO Protocol ADO Protocol
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
NuCana plc NuCana plc

NuCana plc

NCNA
Rankning i aktier #32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Aktiekurs
$1.56
Marknadsvärde
$9.44M
Förändring (1 dag)
-2.20%
Förändring (1 år)
-58.31%
Land
GB
Handel NuCana plc (NCNA)

Kategori

Healthcare
Intäkter för NuCana plc (NCNA)
Intäkter i Aug 2026 TTM: 0
Enligt NuCana plc senaste finansiella rapporter är företagets nuvarande intäkter (TTM) 0. År 2026 hade företaget intäkter på 0 lika med intäkterna år 2026, som var 0. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäkts­historik för NuCana plc från 2026 till 2026
Intäkter vid slutet av varje år
År Intäkter Ändra
Inte tillräckligt med data för de angivna datumen.
Intäkter för liknande företag eller konkurrenter
Företag Intäkter Intäktsdifferens Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE